NZ527173A - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy

Info

Publication number
NZ527173A
NZ527173A NZ527173A NZ52717301A NZ527173A NZ 527173 A NZ527173 A NZ 527173A NZ 527173 A NZ527173 A NZ 527173A NZ 52717301 A NZ52717301 A NZ 52717301A NZ 527173 A NZ527173 A NZ 527173A
Authority
NZ
New Zealand
Prior art keywords
human antibodies
cancer therapy
specific human
selective cancer
chain variable
Prior art date
Application number
NZ527173A
Other languages
English (en)
Inventor
Yocheved Hagai
Janette Lazarovits
Rachel Guy
Orly Lipschitz
Esther Szanthon
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of NZ527173A publication Critical patent/NZ527173A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ527173A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy NZ527173A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
NZ527173A true NZ527173A (en) 2006-03-31

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527173A NZ527173A (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (enExample)
JP (1) JP2004524023A (enExample)
KR (1) KR20030091952A (enExample)
CN (1) CN100374456C (enExample)
AU (1) AU2002246737B2 (enExample)
BR (1) BR0116763A (enExample)
CA (1) CA2433227A1 (enExample)
CZ (1) CZ20031983A3 (enExample)
HU (1) HUP0400775A2 (enExample)
IL (1) IL156690A0 (enExample)
MX (1) MXPA03005944A (enExample)
NZ (1) NZ527173A (enExample)
PL (1) PL365758A1 (enExample)
RU (1) RU2316564C2 (enExample)
WO (1) WO2002059264A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
KR20060107501A (ko) * 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
BR112013000452A2 (pt) * 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
PL3590962T3 (pl) * 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CR20220578A (es) * 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
CN1551886A (zh) 2004-12-01
WO2002059264A2 (en) 2002-08-01
JP2004524023A (ja) 2004-08-12
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
EP1353937A2 (en) 2003-10-22
CZ20031983A3 (cs) 2005-07-13
WO2002059264A3 (en) 2003-03-06
KR20030091952A (ko) 2003-12-03
PL365758A1 (en) 2005-01-10
IL156690A0 (en) 2004-01-04
BR0116763A (pt) 2004-03-09
CA2433227A1 (en) 2002-08-01
EP1353937A4 (en) 2005-04-13
RU2003123100A (ru) 2005-03-10
MXPA03005944A (es) 2005-04-29
HUP0400775A2 (en) 2007-05-02
RU2316564C2 (ru) 2008-02-10

Similar Documents

Publication Publication Date Title
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
DE69632333D1 (de) Monoklonaler antikörper br110 und dessen anwendung
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
CY1108799T1 (el) Αντισωμα αντι- ccr5
EP1881064A3 (en) HCV-Anti-core monoclonal antibodies
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
EP1581096A3 (en) Antigen pipa and antibodies that bind thereto
AU3587599A (en) Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
EP1491555A4 (en) THE GENE FOR THE LIGHT / HEAVY CHAIN OF THE VARIABLE REGION OF THE MONOCLONAL ANTI-HUMAN HEPATOMAN TONOR HAB18
EP1353937A4 (en) SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
AU6171894A (en) Preparation of photoprotein conjugates and methods of use thereof
AU2003226127A1 (en) Antibody libraries
WO2005070456A3 (en) Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
WO2004050849A8 (en) Recombinant immunotoxin and use in treating tumors
WO2003066821A3 (en) Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
EP2633866A3 (en) Combination therapy
AU2002245615A1 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
WO2024163920A3 (en) Anti-cd180 binding molecules and uses thereof
NO20005833D0 (no) Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme
AU6167296A (en) Monoclonal antibody fragment to human ovarian cancers

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed